预约演示
更新于：2025-09-25
Dexibuprofen
右布洛芬
更新于：2025-09-25
概要
基本信息
原研机构- |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 奥地利 (2000-07-27), |
最高研发阶段(中国)批准上市 |
特殊审评优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C13H18O2 |
InChIKeyHEFNNWSXXWATRW-JTQLQIEISA-N |
CAS号51146-56-6 |
关联
27
项与 右布洛芬 相关的临床试验ChiCTR2500104124
Efficacy and Safety of Dexibuprofen in the Treatment of Acute Infection-Induced Fever in Children
ChiCTR2500104114
A comparative study of dexibuprofen or celecoxib for neurosurgical over-the-counter and postoperative analgesia
ChiCTR2500097383
A multi-center, randomized, and positive-drug parallel controlled prospective clinical study to evaluate the efficacy and safety of dexibuprofen in the treatment of children with fever caused by influenza
100 项与 右布洛芬 相关的临床结果
登录后查看更多信息
100 项与 右布洛芬 相关的转化医学
登录后查看更多信息
100 项与 右布洛芬 相关的专利（医药）
登录后查看更多信息
1,588
项与 右布洛芬 相关的文献（医药）2025-10-01BIOORGANIC CHEMISTRY
Sustainable D-Glucose-based ibuprofen ionic liquids/salts for anti-inflammatory applications
Article
作者: P, Krishnaraj ; Reddy, Sabbasani Rajasekhara
Herein, we have developed six novel D-Glucose-derived ibuprofen ionic salts and liquids (GSIS/GSIL-Ibu) utilizing imidazolium, pyridinium, and DABCO cations in combination with S-ibuprofen and R,S-ibuprofen as anions by an acid-base neutralization reaction. The synthesized GSIS/GSIL-Ibu were analysed utilizing various analytical techniques. The novel ibuprofen formulations exhibit enhanced water solubility and improved thermal stability. Of the six compounds, four exhibit higher melting points than the parent drug, while two remain in liquid form at ambient temperature. Cytotoxicity and anti-inflammatory evaluations were performed on the synthesized GSIS/GSIL-Ibu in comparison to ibuprofen utilizing the mouse fibroblast cell line 3T3-L1. Formulations of enantiomerically pure S-ibuprofen demonstrated superior anti-inflammatory efficacy compared to racemic ibuprofen formulations.
2025-09-01JOURNAL OF CHROMATOGRAPHY A
Gradient, reversed-phase HPLC method for simultaneous determination of chemical and enantiomeric impurities of dexibuprofen in a single run
Article
作者: Dobó, Máté ; Tóth, Gergő ; Dombi, Gergely ; Szabó, Zoltán-István ; Simon, Balázs ; Mhammad, Ali
In this work, a gradient reversed-phase HPLC method is presented for the simultaneous determination of four potential chemical impurities in dexibuprofen, as well as its chiral isomer, (R)-ibuprofen. Among nine polysaccharide-based chiral columns tested, enantioselectivity was observed only with the column containing cellulose tris(4-methylbenzoate) under polar organic mode conditions. To enhance enantioresolution, a reversed-phase mode was employed by adding water to the mobile phase. Examination of the water content's impact on retention time revealed a typical reversed-phase retention behavior in alcohol-water mixtures, whereas acetonitrile-water mixtures displayed HILIC-like retention characteristics. A full factorial design optimization strategy was applied to identify the ideal conditions for determining organic and enantiomeric impurities in dexibuprofen. Under the optimized conditions-Lux Cellulose-3 stationary phase using a methanol:water:acetic acid 70:30:0.1 (v/v/v) mobile phase, at a flow rate of 0.5 mL/min and temperature of 35 °C-all target compounds were effectively separated with clear baseline resolution. The initial analysis required 60 min, primarily due to the prolonged retention of highly lipophilic ester impurities. To reduce the analysis time, a gradient elution strategy was developed, successfully cutting the runtime by half. Furthermore, the stability and robustness of the gradient system were confirmed by consistent performance over one hundred consecutive injections. Following regulatory validation guidelines, the developed HPLC method was effectively applied for the quality assessment of commercially available pharmaceutical formulations.
2025-08-01DYES AND PIGMENTS
Tetraphenylethylene based chiral AIEgen for enantioselective detection of chiral acids
作者: Wei, Keyue ; Feng, Hai-Tao ; Zhang, Wangyan ; Li, Qingyang ; Zhang, Xiuhua ; Chen, Miao-Miao ; Qi, Chunxuan ; Zhao, Weiwei
Enantioselective recognition is crucial in pharmaceutical anal. and life sciences but remains a significant challenge.Herein, we constructed two chiral probes named (1R, 2R)-CHDA-2TPE and (1S, 2S)-CHDA-2TPE, which exhibit typical aggregation-induced emission (AIE) properties.The chiral probes show high enantioselectivity to 11 kinds of chiral reagents.Notably, the fluorescence intensity ratio of the probe with L- and D-glutamic acid was up to 88.8.The 1H NMR titration results suggested that the hydrogen bond is response for the recognition.These findings implied that the synthesized probes are promising candidates for analyzing chiral compounds
100 项与 右布洛芬 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 炎症 | 韩国 | 2007-12-31 | |
| 发热 | 中国 | 2001-01-01 | |
| 骨关节炎 | 中国 | - | 2001-01-01 |
| 类风湿关节炎 | 中国 | - | 2001-01-01 |
| 疼痛 | 奥地利 | 2000-07-27 | |
| 疼痛 | 意大利 | 2000-07-27 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 术后疼痛 | 临床2期 | 中国 | 2025-09-24 | |
| 镇痛 | 临床2期 | 中国 | 2021-07-13 | |
| 麻醉 | 临床2期 | 中国 | 2020-11-16 | |
| 麻醉 | 临床2期 | 中国 | 2020-11-16 | |
| 急性疼痛 | 临床2期 | 美国 | 2018-01-12 | |
| 肌痛 | 临床2期 | 美国 | 2015-01-01 | |
| 痛经 | 临床1期 | 中国 | 2023-05-17 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 251 | (Active Arm) | 遞鹽壓淵淵網觸獵衊遞(廠鏇鏇積積憲選壓積壓) = 醖淵獵餘願襯齋網壓遞 夢醖鹽網膚餘醖遞鑰獵 (艱顧鏇糧繭襯築夢鬱範, 31.311) 更多 | - | 2022-01-25 | ||
Vehicle (Placebo Arm) | 遞鹽壓淵淵網觸獵衊遞(廠鏇鏇積積憲選壓積壓) = 鬱繭壓糧網憲繭構範鹽 夢醖鹽網膚餘醖遞鑰獵 (艱顧鏇糧繭襯築夢鬱範, 29.763) 更多 | ||||||
临床3期 | 263 | 糧糧齋壓廠獵繭廠構餘(鏇願繭窪膚蓋夢獵製鑰) = 糧餘觸壓繭壓願艱襯願 鹽蓋構齋築築簾繭餘鏇 (製淵醖壓糧餘鏇廠憲艱 ) | - | 2018-06-23 | |||
糧糧齋壓廠獵繭廠構餘(鏇願繭窪膚蓋夢獵製鑰) = 選夢窪糧憲餘製憲選鹽 鹽蓋構齋築築簾繭餘鏇 (製淵醖壓糧餘鏇廠憲艱 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用